Literature DB >> 10973451

Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines.

D J Sikkema1, K E Friedman, B Corsaro, A Kimura, S W Hildreth, D V Madore, S A Quataert.   

Abstract

A new meningococcal group C-CRM(197) conjugate vaccine (MnCC; Meningitec) has been evaluated in multiple clinical trials in the United States and most recently has been approved for routine administration in the United Kingdom. Meningococcal serogroup C (MnC)-specific immunoglobulin G (IgG) antibodies in pre- and postimmunization sera obtained from healthy U.S. adults, toddlers, and infants were quantitated by enzyme-linked immunosorbent assay (ELISA) and by an antibody-dependent, complement-mediated serum bactericidal assay (SBA). Serogroup-specific IgG antibody (micrograms per milliliter) in adults immunized either with the quadrivalent polysaccharide (A, C, Y, and W-135) vaccine or with MnCC showed a strong correlation (r = 0.848 and 0.934, respectively) by linear regression analysis with SBA. Sera from infants immunized with the MnCC (n = 30) and an age-matched unimmunized control group (n = 15) were also analyzed. Linear regression analysis of serum bactericidal and IgG ELISA data from sera obtained at 2 months of age (preimmunization) showed no correlation; however, a high degree of correlation was observed at time points after two (r = 0.877) and three (r = 0.951) immunizations, where significant rises in anti-MnC polysaccharide antibodies occurred relative to the age-matched control group. Infants previously primed with 3 doses of MnCC were given a booster dose of conjugate vaccine at 12 to 15 months of age. The correlation coefficient of ELISA to SBA for combined pre- and postbooster data was r = 0.836 (n = 48 pairs). In conclusion, increases in serum bactericidal activity in immunized adult, toddler, and infant populations were found to correlate very well with increases in serogroup-specific IgG concentrations, whereas the correlation between these two assays in nonimmunized 2-month-old infants was poor. Characterizing the relationship between these methods is important for understanding the significance of antigen-specific antibody concentrations relative to vaccine performance and protection from disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973451      PMCID: PMC95952          DOI: 10.1128/CDLI.7.5.764-768.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  30 in total

1.  Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3).

Authors:  C A Alper; N Abramson; R B Johnston; J H Jandl; F S Rosen
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

2.  Antibodies to lipopolysaccharides of Escherichia coli serogroups O5 and O165 in healthy adults.

Authors:  C Jenkins; H Chart
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

3.  Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity.

Authors:  B H Petersen; J A Graham; G F Brooks
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

4.  Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis.

Authors:  D Lim; A Gewurz; T F Lint; M Ghaze; B Sepheri; H Gewurz
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

5.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

6.  Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children.

Authors:  H Käyhty; V Karanko; H Peltola; S Sarna; P H Mäkelä
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

7.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

8.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  9 in total

1.  Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide.

Authors:  Peter C Giardina; Emma Longworth; Renee E Evans-Johnson; Michaelene L Bessette; Hong Zhang; Ray Borrow; Dace Madore; Philip Fernsten
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

2.  A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.

Authors:  Kenneth T Mountzouros; Kelly A Belanger; Alan P Howell; Garvin S Bixler; Dace V Madore
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  Observed parent-child relationship quality predicts antibody response to vaccination in children.

Authors:  Thomas G O'Connor; Hongyue Wang; Jan A Moynihan; Peter A Wyman; Jennifer Carnahan; Gerry Lofthus; Sally A Quataert; Melissa Bowman; Anne S Burke; Mary T Caserta
Journal:  Brain Behav Immun       Date:  2015-04-09       Impact factor: 7.217

4.  Depressive symptoms and immune response to meningococcal conjugate vaccine in early adolescence.

Authors:  Thomas G O'Connor; Jan A Moynihan; Peter A Wyman; Jennifer Carnahan; Gerry Lofthus; Sally A Quataert; Melissa Bowman; Mary T Caserta
Journal:  Dev Psychopathol       Date:  2014-11

5.  Effect of antigen coating conditions on enzyme-linked immunosorbent assay for detection of immunoglobulin G antibody to Neisseria meningitidis serogroup Y and W135 capsular polysaccharide antigens in serum.

Authors:  Peter C Giardina; Renee E Evans; Daniel J Sikkema; Dace Madore; Stephen W Hildreth
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

6.  Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1.

Authors:  Arianna Marini; Omar Rossi; Maria Grazia Aruta; Francesca Micoli; Simona Rondini; Serafina Guadagnuolo; Isabel Delany; Ian R Henderson; Adam F Cunningham; Allan Saul; Calman A MacLennan; Oliver Koeberling
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

7.  Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine.

Authors:  Johannes Elias; Jamie Findlow; Ray Borrow; Angelika Tremmel; Matthias Frosch; Ulrich Vogel
Journal:  J Occup Med Toxicol       Date:  2013-03-04       Impact factor: 2.646

8.  Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008.

Authors:  Caroline L Trotter; Seydou Yaro; Berthe-Marie Njanpop-Lafourcade; Aly Drabo; Sita S Kroman; Regina S Idohou; Oumarou Sanou; Leah Bowen; Helen Findlow; Serge Diagbouga; Bradford D Gessner; Ray Borrow; Judith E Mueller
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

Review 9.  Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Authors:  Robert G K Donald; Julio Cesar Hawkins; Li Hao; Paul Liberator; Thomas R Jones; Shannon L Harris; John L Perez; Joseph J Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.